Zacks: Brokerages Expect Allogene Therapeutics Inc (ALLO) to Announce -$0.40 EPS

Share on StockTwits

Wall Street analysts predict that Allogene Therapeutics Inc (NASDAQ:ALLO) will report earnings of ($0.40) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Allogene Therapeutics’ earnings. The highest EPS estimate is ($0.39) and the lowest is ($0.43). The company is scheduled to issue its next quarterly earnings report before the market opens on Tuesday, May 7th.

On average, analysts expect that Allogene Therapeutics will report full-year earnings of ($2.13) per share for the current fiscal year, with EPS estimates ranging from ($2.50) to ($2.04). For the next fiscal year, analysts expect that the company will report earnings of ($2.56) per share, with EPS estimates ranging from ($2.93) to ($2.20). Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Allogene Therapeutics.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings data on Friday, March 8th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10).

A number of equities analysts have weighed in on the stock. William Blair assumed coverage on shares of Allogene Therapeutics in a research report on Wednesday, March 13th. They issued an “outperform” rating for the company. Cowen reissued a “buy” rating on shares of Allogene Therapeutics in a research report on Friday, March 8th. Raymond James assumed coverage on shares of Allogene Therapeutics in a research report on Thursday, March 14th. They issued an “outperform” rating and a $40.00 price objective for the company. Zacks Investment Research raised shares of Allogene Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 25th. Finally, JPMorgan Chase & Co. reissued a “hold” rating and issued a $29.00 price objective on shares of Allogene Therapeutics in a research report on Monday, March 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $38.00.

Several hedge funds have recently modified their holdings of ALLO. Strs Ohio bought a new position in shares of Allogene Therapeutics during the fourth quarter worth about $156,000. Rhumbline Advisers bought a new position in Allogene Therapeutics in the fourth quarter worth about $829,000. Creative Planning bought a new position in Allogene Therapeutics in the fourth quarter worth about $544,000. Shikiar Asset Management Inc. bought a new position in Allogene Therapeutics in the fourth quarter worth about $1,056,000. Finally, TD Asset Management Inc. bought a new position in Allogene Therapeutics in the fourth quarter worth about $674,000. 51.60% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:ALLO opened at $30.07 on Friday. The stock has a market capitalization of $3.57 billion and a price-to-earnings ratio of -4.57. Allogene Therapeutics has a 1-year low of $21.67 and a 1-year high of $35.55.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.

Read More: What is the balance sheet?

Get a free copy of the Zacks research report on Allogene Therapeutics (ALLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.